Vancomycin in Pediatric Patients with Solid or Hematological Malignant Disease: Predictive Performance of a Population Pharmacokinetic Model and New Optimized Dosing Regimens.

CONCLUSION: The model previously proposed by Guilhaumou et al. in pediatric patients with solid or hematological malignant disease was externally validated. Simulations have enabled the description of new dosage schedules and creation of a chart to help clinicians adapt vancomycin dosage. PMID: 29736878 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29736878?dopt=Abstract

Source: Paediatric Drugs - May 8, 2018 Category: Pediatrics Authors: Marsot A, Gallais F, Galambrun C, Coze C, Blin O, Andre N, Guilhaumou R Tags: Paediatr Drugs Source Type: research